Riad Salem, MD, Northwestern University Feinberg School of Medicine

home / authors / riad-salem-md-northwestern-university-feinberg-school-of-medicine

Articles

Future Directions for mHCC

Future Directions for mHCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center
July 24th 2020

Read More

mHCC: Influence of PD-L1 Inhibitors on Second-Line Therapy

mHCC: Influence of PD-L1 Inhibitors on Second-Line Therapy

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center
July 24th 2020

Read More

ASCO 2020 Data for Treatment of Advanced HCC

ASCO 2020 Data for Treatment of Advanced HCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center
July 24th 2020

Read More

ASCO 2020: HIMALAYA Trial for Advanced HCC

ASCO 2020: HIMALAYA Trial for Advanced HCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center
July 24th 2020

Read More

Role of VEGF TKIs for Treatment of HCC

Role of VEGF TKIs for Treatment of HCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center
July 24th 2020

Read More

Safety of PD-L1 Inhibitors in mHCC

Safety of PD-L1 Inhibitors in mHCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center
July 24th 2020

Read More

IMbrave150 Trial: Frontline Treatment of Advanced HCC

IMbrave150 Trial: Frontline Treatment of Advanced HCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center
July 24th 2020

Read More

Initiation of Systemic Therapy for mHCC

Initiation of Systemic Therapy for mHCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center
July 24th 2020

Read More

Overview and Diagnosis of HCC

Overview and Diagnosis of HCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center
July 24th 2020

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need